December 15, 2023

A week af­ter one obe­si­ty biotech, Car­mot Ther­a­peu­tics, backed out of its IPO plans in fa­vor of a $2.7 bil­lion sale to Roche, an­oth­er an­nounced

PhRMA pres­i­dent Stephen Ubl ar­gued Thurs­day that the Biden ad­min­is­tra­tion’s new pro­pos­al on the use of march-in rights has “plant­ed the seeds of un­cer­tain­ty” around

House Re­pub­li­cans have threat­ened the FDA with a sub­poe­na, say­ing the agency failed to pro­vide in­for­ma­tion on for­eign drug in­spec­tions. “The US can­not af­ford ad­di­tion­al

The FDA ap­proved US WorldMeds’ eflor­nithine as a ther­a­py to re­duce the risk of re­lapse in adult and pe­di­atric pa­tients with high-risk neu­rob­las­toma who have

Sen­ate Health Com­mit­tee chair Sen. Bernie Sanders (I-VT) said he will in­tro­duce leg­is­la­tion that, if signed in­to law, would low­er pre­scrip­tion drug costs in the

Am­gen’s $28 bil­lion Hori­zon Ther­a­peu­tics takeover came with rare in­flam­ma­to­ry dis­ease med­i­cines and, ap­par­ent­ly, a tee time. The com­pa­ny will be­come ti­tle spon­sor of the

RSV vac­cine man­u­fac­tur­ers Sanofi and As­traZeneca will make 230,000 more dos­es of their im­mu­niza­tions for in­fants avail­able be­gin­ning in Jan­u­ary to ad­dress high de­mand, the

Pub­li­cis Health is get­ting a new CEO, al­though he’s al­ready a fa­mil­iar face in the Pub­li­cis agency net­work. Stephen Far­quhar will step in­to the role

Wel­come to End­points News’ man­u­fac­tur­ing news briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more. NightHawk is to be­come a